# Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

Study · id `cardio:ct-nct02390375` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02390375](<https://clinicaltrials.gov/study/NCT02390375>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02390375

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 348 participants.

## Technical summary

Registry record NCT02390375. Randomized; double masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 348 participants (enrolled count; ClinicalTrials.gov record NCT02390375, source copy `cardio:ctgov-nct02390375-2016-10-10`, retrieved 2026-10-31)
- Start date: 2014-11 (registry gives no type) (ClinicalTrials.gov record NCT02390375, source copy `cardio:ctgov-nct02390375-2016-10-10`, retrieved 2026-10-31)
- Primary completion: 2016-04 (actual) (ClinicalTrials.gov record NCT02390375, source copy `cardio:ctgov-nct02390375-2016-10-10`, retrieved 2026-10-31)
- Completion: 2016-05 (actual) (ClinicalTrials.gov record NCT02390375, source copy `cardio:ctgov-nct02390375-2016-10-10`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT02390375, source copy `cardio:ctgov-nct02390375-2016-10-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02390375-2016-10-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia
- Condition: Hypercholesterolemia
- Intervention (Drug): DW-0929
- Intervention (Drug): DW-0929
- Intervention (Drug): DW-0929
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Rosuvastatin
- Lead sponsor: Daewon Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Daewon Pharmaceutical Co., Ltd. (`cardio:org-daewon-pharmaceutical-co-ltd`)

## Provenance

Content hash: a2cca0a7a401a6ae96bbfd54ae1e02067c86329487136397cdc62e6045c38ad9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
